PMDA Guidance on Risk Management Plan (RMP)
On 29 July 2022 the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) posted RMP page renewal, Q&A, templates, instructions and publication.
Read more online
Read
Questions & Answers - Practical Arrangements on the Companion Diagnostics Consultation Procedure to the European Medicines Agency by Notified Bodies
1 July 2022 — EMA published updated Q&A guidance on diagnostic consultation procedures.
Read the pdf
Read
Guidance on Applying the 2021 Advertising Code Rules
1 July 2022 — Australian Therapeutic Goods Administration (TGA) published the guidance on applying the advertising code rules for therapeutic goods.
Read the pdf
Read
Guideline on Advertising, etc. of Medicinal Products for Human Use
5 July 2022 — Danish Medicines Agency updated guideline on advertising of medicinal products for human use.
Read more online
Read
Identifying Trading Partners Under the Drug Supply Chain Security Act
5 July 2022 — FDA issued the draft guidance for industry. Submit comments by 05 September 2022.
Read more online
Read
OPEN Pilot: One-year Review and Recommendations
7 July 2022 — EMA published the OPEN Pilot report.
Read the pdf
Read
Consultation on Regulatory Guidelines for Laboratory Developed Tests (LDTs)
12 July 2022 — Singapore Health Sciences Authority (HAS) announced the release of a draft regulatory guidelines for LDTs for stakeholders' consultation.
Read more online
Read
Information about the Raw Data Proof-of-Concept Pilot for Industry
12 July 2022 — EMA announced the availability of access to raw data for marketing authorization and post-authorization applications submitted to the EMA.
Read the pdf
Read
GCP Inspection Site Report Template on Behalf of the EMA
12 July 2022 — EMA published the updated GCP inspection procedures for appendix 1 to INS-GCP-4 procedure for reporting of GCP inspections requested by the CHMP.
Read the pdf
Read
Joint Controllership Arrangement: EudraVigilance Human (EV) Personal Data Capture
13 July 2022 — EMA published legal framework for the purpose of processing personal data captured in EudraVigilance Human (EV) administered by EMA
Read the pdf
Read
Instructions for Use — Patient Labeling for Human Prescription Drug and Biological
14 July 2022 — FDA published the final guidance for industry.
Read more online
Read
Horizon Scanning Case Study: Point of Care Manufacture
15 July 2022 — UK MHRA published the horizon scanning case study.
Read more online
Read
The ICH Drug Interaction Studies M12 Draft Guideline Now Available Online
ICH announced the availability of the M12 draft guideline presentation.
Read the pdf
Read
Technology Capability Investment Plan
15 July 2022 — EMA published technology capability investment plan for becoming the digital hub for the European Medicines Regulatory Network.
Read the pdf
Read
European Medicines Agency’s Data Protection Notice for EudraVigilance Human (EV)
15 July 2022 — EMA published updated data protection notice for EudraVigilance Human.
Read the pdf
Read
Questions and Answers - Complex Clinical Trials
2 June 2022 — European Commission published updated Q&A guidance on complex clinical trials, version 2022-05-23.
Read more online
Read
Compliance Monitor (CM) Overview and Application Process
15 June 2022 — MHRA published updated guidance on the eligibility of the compliance monitor.
Read more online
Read
Marketing Authorization Application (MAA) Submission Dates for 150-days National and European Commission Decision Reliance Procedures
20 June 2022 — MHRA published updated guidance on MAA submission dates.
Read more online
Read
Guidance on Handling of Decentralized and Mutual Recognition Procedures Which are Approved or Pending
24 June 2022 — MHRA published updated guidance on the approach the MHRA intends to take for products approved or pending in decentralized procedure (DCP) or mutual recognition procedures (MRP).
Read more online
Read
European Medicines Agency Post-Authorization Procedural Advice for Users of the Centralized Procedure
20 June 2022 — EMA published updated Q&A guidance on extensions of marketing authorizations.
Read the pdf
Read
European Medicines Agency Pre-Authorization Procedural Advice for Users of the Centralized Procedure
20 June 2022 — EMA published updated pre-authorization Q&A guidance.
Read the pdf
Read
Updated IRIS Guide for Industry and Individual Applicants
28 June 2022 — EMA published the updated IRIS guide on how to create and submit scientific applications.
Read the pdf
Read
Workshop Report on Data Quality Framework for Medicines Regulation
29 June 2022 — EMA published workshop report on data quality framework for medicines regulation.
Read the pdf
Read
eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) Data-Entry Tool (EVWEB) User Manual
7 June 2022 — EMA published version 5.7 of the EVWEB user manual.
Read the pdf
Read
Article 57 User Interface (UI) Installation Guide
7 June 2022 — EMA published updated installation guide on article 57 UI components and initial set-up.
Read the pdf
Read
Orphans: Regulatory and Procedural Guidance and Forms
9 June 2022 — EMA announced updated procedural guidance documents on orphan designation.
Read more online
Read
Changing the Name or Address of a Sponsor
9 June 2022 — EMA announced update for submitting a request to change the name or address.
Read more online
Read
Mandatory Use of ISO/ICH E2B(R3) Individual Case Safety Reporting in the EU: Hands-on Training Using the EudraVigilance System
15 June 2022 — EMA announced EudraVigilance System online training course.
Read more online
Read
Technical Performance Assessment of Quantitative Imaging in Radiological Device Premarket Submissions
16 June 2022 — FDA published the final guidance for industry and FDA staff.
Read more online
Read
Non-Clinical Performance Assessment of Tissue Containment Systems Used During Power Morcellation Procedures
21 June 2022 — FDA issued draft guidance for industry and FDA staff. Submit comments by 22 August 2022.
Read more online
Read
Assessing the Effects of Food on Drugs in INDs and NDAs – Clinical Pharmacology Considerations
24 June 2022 — FDA published final guidance.
Read more online
Read
Clinical Pharmacology Considerations for the Development of Oligonucleotide Therapeutics
27 June 2022 — FDA issued draft guidance for comments by 25 September 2022.
Read more online
Read
Renal Cell Carcinoma: Developing Drugs and Biologics for Adjuvant Treatment
27 June 2022 — FDA published final industry guidance on the treatment of renal cell carcinoma.
Read more online
Read
Bladder Cancer: Developing Drugs and Biologics for Adjuvant Treatment
27 June 2022 — FDA published final industry guidance on the treatment of bladder cancer.
Read more online
Read
Patient-Focused Drug Development: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments
29 June 2022 — FDA issued draft guidance for comments by 28 September 2022.
Read more online
Read
Electromagnetic Compatibility (EMC) of Medical Devices
6 June 2022 — FDA issued guidance on EMC for industry and FDA staff.
Read more online
Read
Q9(R1) Quality Risk Management
14 June 2022 — FDA issued draft guidance for comments by 15 July 2022.
Read more online
Read
Voluntary Consensus Standards Recognition Program for Regenerative Medicine Therapies
15 June 2022 — FDA issued draft guidance for comments by 14 September 2022.
Read more online
Read
IRIS Guide for Applicants
On 16 May 2022 the EMA published IRIS guide on how to create and submit scientific applications, for industry and individual applicants, version 2.10.
Read the pdf
Read
Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production
On 16 May 2022 the FDA published Final Level 2 revised guidance.
Read more online
Read
Safety Considerations for Container Labels and Carton Labeling Design to Minimize Medication Errors
On 18 May 2022 the FDA published the final guidance on safety considerations for labeling.
Read more online
Read
How to Notify the MHRA about a Clinical Investigation for a Medical Device
On 19 May 2022 the UK MHRA updated the guidance on notifying the MHRA of the intention to conduct a clinical investigation for medical devices.
Read more online
Read
Annual Report of the Good Clinical Practice Inspectors’ Working Group 2020
On 20 May 2022 the EMA published the annual report of the GCP IWG, which was adopted by the GCP IWG on 30 April 2022.
Read the pdf
Read
Risk Management Plans to Mitigate the Potential for Drug Shortages
On 20 May 2022 the FDA published the draft guidance on risk management plans for drug shortages. Comments may be submitted until 19 July 2022.
Read more online
Read
Medicines Shortages: Regulatory Processes to Manage Supply Disruptions
On 23 May 2022 the UK MHRA published the guidance on regulatory processes to manage supply disruptions.
Read more online
Read
Addendum to the Guideline on the Evaluation of Medicinal Products Indicated for Treatment of Bacterial Infections to Address Paediatric-specific Clinical Data Requirements
On 24 May 2022 the EMA published the addendum to the guideline on evaluation of medicinal products indicated for treatment of bacterial infections.
Read the pdf
Read
Guideline on the Evaluation of Medicinal Products Indicated for Treatment of Bacterial Infections
On 24 May 2022 the EMA published the revised guideline on the evaluation of human medicines for the treatment of bacterial infections, revision 3.
Read the pdf
Read
Clinical Trials Highlights – May 2022
On 25 May 2022 the EMA published Clinical Trials Highlights - Issue 9.
Read the pdf
Read
Supervise a Clinical Trial: Inspection Records – CTIS Training Programme – Module 16
On 25 May 2022 the EMA published FAQs on clinical trial inspection records.
Read the pdf
Read
Q&A on the Interface between Regulation (EU) 536/2014 on Clinical Trials for Medicinal Products for Human Use (CTR) and Regulation (EU) 2017/746 on in vitro Diagnostic Medical Devices (IVDR)
On 25 May 2022 the European Commission published Q&A guidance on the interface between the EU CTR and IVDR.
Read more online
Read
Antibacterial Therapies for Patients with an Unmet Medical Need for the Treatment of Serious Bacterial Diseases – Questions and Answers (Revision 1)
On 25 May 2022 the FDA published the draft Q&A guidance, revision 1. Comments may be submitted until 24 July 2022.
Read more online
Read
Importation of Prescription Drugs Final Rule Questions and Answers; Small Entity Compliance Guide
On 25 May 2022 the FDA published the final Q&A guidance for industry.
Read more online
Read
New Regulations Applicable to In Vitro Diagnostic Medical Devices
On 26 May 2022 the Swissmedic announced the entry into force of the new regulations on in vitro diagnostic medical devices.
Read more online
Read
Advanced Prostate Cancer: Developing Gonadotropin-Releasing Hormone Analogues
On 27 May 2022 the FDA published the final guidance for industry.
Read more online
Read
Questions and Answers Document – Regulation (EU) 536/2014
On 30 May 2022 the European Commission published Q&A guidance on the Clinical Trials Regulation, version 6.1.
Read more online
Read
Updated Frequently Asked Questions about Parallel Distribution
On 31 May 2022 the EMA published updated FAQs about parallel distribution.
Read the pdf
Read
Risklick Provides Clinical Trial Educational Programs
The Clinical Trial Academy Essential Program provided by Risklick is aimed to address the difficulties in developing an ideal clinical trial protocol.
Read more online
Read
Use of Circulating Tumor DNA for Early-Stage Solid Tumor Drug Development
On 2 May 2022 the FDA announced the availability of the draft guidance for industry.
Read more online
Read
ICH Guideline Q3D (R2) on Elemental Impurities
On 3 May 2022 the EMA published step 5 of the revised ICH guideline Q3D (R2) on elemental impurities.
Read the pdf
Read
Supplements for Approved Premarket Approval (PMA) or Humanitarian Device Exemption (HDE) Submissions During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency (Revised)
On 4 May 2022 the FDA published the final guidance for industry and FDA staff.
Read more online
Read
Clinical Pharmacology Considerations for Human Radiolabeled Mass Balance Studies
On 5 May 2022 the FDA published the draft guidance for industry. Comments may be submitted until 4 August 2022.
Read more online
Read
Fostering Medical Device Improvement: FDA Activities and Engagement with the Voluntary Improvement Program
On 5 May 2022 the FDA published the draft guidance for industry and FDA staff. Comments may be submitted until 5 July 2022.
Read more online
Read
Updated Good Clinical Practice (GCP) Inspection Procedures
On 5 May 2022 the EMA announced the updates of the guidance on GCP inspection procedures.
Read more online
Read
Guidelines on MedDRA Coding for Drug Marketing Authorization Holders
On 6 May 2022 the Chinese NMPA issued the MedDRA coding guidelines for the MAHs.
Read more online
Read
Compliance Monitor Process (Part 2) – CM Role and Application Process
On 10 May 2022 the UK MHRA Inspectorate published the second part of the compliance monitor process.
Read more online
Read
Benefit-Risk Considerations for Product Quality Assessments
On 10 May 2022 the FDA published the draft guidance for industry. Comments may be submitted until 10 July 2022.
Read more online
Read
NMPA Guidelines for Pharmacovigilance Inspection
On 15 April 2022 the Chinese NMPA published the announcement of distributing the PV inspection guidelines (NMPA [2022] No. 17).
Read more online
Read
Annual Report of the Good Manufacturing and Distribution Practice Inspectors Working Group 2021
On 20 April 2022 the EMA published annual report of the GMP/GDP Inspectors Working Group (IWG).
Read the pdf
Read
Overview of Comments Received on ICH Guideline Q9 (R1) on Quality Risk Management
On 20 April 2022 the EMA published comments on ICH guideline Q9(R1) on quality risk management.
Read the pdf
Read
2021 Annual Report on EudraVigilance for the European Parliament, the Council and the Commission
On 20 April 2022 the EMA published the 2021 EudraVigilance annual report (1 Jan to 31 Jan 2021).
Read the pdf
Read
Compilation of Union Procedures on Inspections and Exchange of Information
On 20 April 2022 the EMA published the compilation of union procedures on inspections and exchange of information.
Read the pdf
Read
PRAC Strategy on Measuring the Impact of Pharmacovigilance Activities
On 21 April 2022 the EMA issued PV guidance revision 2 on the Pharmacovigilance Risk Assessment Committee (PRAC) strategy.
Read the pdf
Read
Refuse to Accept Policy for 510(k)s
On 21 April 2022 the FDA published the final guidance for industry and FDA staff.
Read more online
Read
Drug Products, Including Biological Products, that Contain Nanomaterials
On 21 April 2022 the FDA published the final guidance for industry on drug products with nanomaterials.
Read more online
Read
Providing Submissions in Electronic Format — Postmarketing Safety Reports
On 27 April 2022 the FDA published the final guidance on electronic submissions of postmarketing safety reports for industry.
Read more online
Read
ICH E8(R1) General Considerations for Clinical Studies
On 28 April 2022 the ICH announced that Step 4 - Introductory Training Presentation – is available on the ICH website.
Read the pdf
Read
Compliance Monitor (CM) Overview and Application Process
On 29 April 2022 the UK MHRA published guidance on the CM overview and application process.
Read more online
Read
Update to Guidance document "Information on PSUR / PBRER submission"
Effective 1 April 2022, Swissmedic updated the Guidance document, allowing a transition period of 30 days.
Read more online
Read
Good Clinical Practice for Medical Devices
On 2 April 2022 the Chinese NMPA issued an announcement for the GMP for clinical trials of medical devices (No. 28 of 2022).
Read more online
Read
Guidance for Applicants/MAHs Involved in GMP and GCP Inspections Coordinated by EMA
On 2 April 2022 the EMA published guidance for applicants/MAHs involved in GMP and GCP inspections.
Read the pdf
Read
M7(R2) Addendum: Application of The Principles of the ICH M7 Guideline to Calculation of Compound-Specific Acceptable Intakes
On 6 April 2022 the FDA published draft guidance on ICH M7 addendum for industry.
Read more online
Read
Chronic Hepatitis B Virus Infection: Developing Drugs for Treatment
On 6 April 2022 the FDA published the final guidance on developing drugs for chronic hepatitis B virus infection.
Read more online
Read
Use of Whole Slide Imaging in Nonclinical Toxicology Studies: Questions and Answers
On 7 April 2022 the FDA published the draft Q&A guidance for industry. Comments may be submitted until 7 Jun 2022.
Read more online
Read
General Considerations for Clinical Studies – E8(R1)
On 7 April 2022 the FDA published the final guidance on ICH E8(R1) general considerations for clinical studies.
Read more online
Read
Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions
On 8 April 2022 the FDA published draft guidance on cybersecurity in medical devices for industry and FDA staff. Comments may be submitted until 7 Jul 2022.
Read more online
Read
Draft Guidance Document on How to Approach the Protection of Personal Data and Commercially Confidential Information in Documents Uploaded and Published in the Clinical Trial Information System (CTIS)
On 8 April 2022 the EMA published draft guidance on protection of personal data and commercially confidential information in CTIS.
Read the pdf
Read
Providing Regulatory Submissions in Electronic and Non-Electronic Format—Promotional Labeling and Advertising Materials for Human Prescription Drugs
On 11 April 2022 the FDA published the final guidance for industry.
Read more online
Read
Updated Frequently Asked Questions about Parallel Distribution
On 12 April 2022 the EMA updated the FAQ/General Question No. 22.
Read more online
Read
Diversity Plans to Improve Enrollment of Participants from Underrepresented Racial and Ethnic Populations in Clinical Trials
On 13 April 2022 the FDA announced the availability of the draft guidance for industry.
Read more online
Read
Updated IRIS Guide for Applicants
On 13 April 2022 the EMA published version 2.8 of the IRIS guide on how to create and submit scientific applications, for industry and individual applicants.
Read the pdf
Read
Questions and Answers Document – Regulation (EU) 536/2014
On 13 April 2022 the European Commission published Q&A guidance on Clinical Trials Regulation (EU) 536/2014, version 6.
Read more online
Read
Detailed Guidance on ICSRs in the Context of COVID-19
On 13 April 2022 the EMA published updated guidance revision 3, clarifying the validity and coding of ICSRs linked to COVID-19.
Read the pdf
Read
Points to Consider on the Impact of the War in Ukraine on Methodological Aspects of Ongoing Clinical Trials
On 13 April 2022 the EMA published guidance on actions for ongoing clinical trials affected by the war in Ukraine.
Read the pdf
Read
Bioavailability Studies Submitted in NDAs or INDs – General Considerations
On 14 April 2022 the FDA published final guidance on general considerations for bioavailability studies submitted in NDAs or INDs.
Read more online
Read
Updated EMA EudraVigilance Registration Manual
On 17 March 2022 the EMA updated the EudraVigilance registration manual.
Read the pdf
Read
Updated EMA Post-authorization Procedural Advice for Users of the Centralized Procedure
On 18 March 2022 the EMA updated the EudraVigilance registration manual.
Read the pdf
Read
Certain Ophthalmic Products: Policy Regarding Compliance With 21 CFR Part 4
On 22 March 2022 the FDA published final guidance for industry.
Read more online
Read
An Acceptable Circular of Information for the Use of Human Blood and Blood Components
On 22 March 2022 the FDA published final guidance for industry.
Read more online
Read
"Measures for the Supervision and Administration of Medical Device Production" and "Measures for the Supervision and Administration of Medical Device Operation"
On 23 March 2022 the Chinese NMPA published two guidelines on medical device production and operation.
Read more online
Read
Announcement on the Release of Guidelines for the Preparation of Annual Self-inspection Reports for Medical Device Quality Management Systems (No. 13 of 2022)
On 24 March 2022 the Chinese NMPA announced the release of guidelines on annual self-inspection reports for medical device quality management systems effective 1 May 2022.
Read more online
Read